Clinical Trial Update: Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy, safety, and tolerability of Rabeprazole ER 50 mg compared with placebo in subjects with symptomatic gastroesophageal refl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• Rabeprazole ER 50 mg (rabeprazole)

Snippet

Sponsor: Eisai Inc. | Conditions: Symptomatic Gastroesophageal Reflux Disease (sGERD) | Phase 3 | Status: COMPLETED | Results posted: 2016-02-02